The rates of population-based screening and diagnosis of breast, cervical, and colorectal cancer in the USA in 2021 remained below those reported before the COVID-19 pandemic, researchers caution in  JAMA Oncology .

The strategies were: no screening; five age-based screening strategies; adaptive screening, where men with an initial prostate-specific antigen level of < 1.5 ng/mL are screened every 6 years and those above this level are screened every 4 years; and two polygenic risk-stratified screening strategies.

A cohort study has found a significant association between annual prostate-specific antigen screening and a reduced risk for prostate cancer-specific mortality among non-Hispanic Black, but not White, men.

A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.

US research suggests that the expansion of the US Preventive Services Taskforce eligibility criteria for lung cancer screening in 2021 may be helping to lessen racial disparities in the uptake of screening.

Fewer than one in 10 older men initiating androgen deprivation therapy for localized or regional prostate cancer receive dual-energy X-ray absorptiometry screening to assess bone mineral density, US study findings indicate.

Magnetic resonance imaging screening plus pre-emptive treatment does not significantly reduce clinical spinal cord compression rates in patients with castration-resistant prostate cancer and spinal metastasis, PROMPTS trial data show.

Rates of prostate-specific antigen testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.

Initiating biennial breast screening for Black women at age 40 years rather than the US standard of 50 years could substantially reduce Black–White breast cancer mortality disparities without increasing harms, modelling data suggest.

A survey of US oncologists and physicians has shown that their perceived barriers toward genetic counseling and testing for breast cancer vary by patients' race.

The Stockholm3 risk prediction tool performs at least as well as prostate-specific antigen screening for the detection of clinically significant prostate cancer, research suggests.

A US study has found that breast cancer screening rates declined during the COVID-19 pandemic, with the largest reductions among Black and Latinx women, which may exacerbate pre-existing disparities.

A population-based, screening-by-invitation trial has demonstrated that a combined MRI-guided plus standard biopsy approach is noninferior to standard biopsy with regard to the detection of clinically significant prostate cancer in men with increased prostate-specific antigen levels.

Regular prostate cancer screening in young African–American men significantly reduces the likelihood of metastatic disease at the time of diagnosis, show study findings reported at the 2021 ASCO Annual Meeting.

The declines in breast cancer screening during the COVID-19 pandemic are more marked among women from minority communities and those living in rural areas, report US researchers.

Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.

The US Preventive Services Task Force has updated its recommendations for lung cancer screening with low-dose computed tomography among current and former smokers.

Biparametric magnetic resonance imaging identifies more clinically significant prostate cancers than prostate-specific antigen screening without increasing the rate of overdiagnosis or need for biopsies, suggest the IP1-PROSTAGRAM results.

Breast cancer screening by clinical breast examination is a viable approach in low and middle income countries, suggests an Indian cluster randomized controlled trial.

The Taiwan Lung Cancer Screening in Never-Smoker Trial suggests that low-dose computed tomography screening may help to detect early-stage disease in never smokers at high risk for developing lung cancer.